POC Lipid Testing Market - Global Forecast 2025-2032

The point-of-care lipid testing market is evolving rapidly, empowering healthcare organizations to enhance diagnostic agility and expand access to cardiovascular care. Senior decision-makers face heightened demand for immediate, integrated diagnostics that support patient outcomes and operational resilience.

Market Snapshot: Point-of-Care Lipid Testing Market

The global point-of-care lipid testing market is projected to grow from USD 333.33 million in 2024 to USD 354.86 million in 2025, representing a 6.44% compound annual growth rate and reaching USD 549.32 million by 2032. This strong market performance is driven by rising demand for onsite diagnostic solutions, allowing faster cardiovascular risk assessment in varied clinical environments. Health systems are accelerating the integration of real-time lipid testing, which streamlines care delivery, improves diagnostic process scalability, and aligns with global shifts toward decentralized healthcare models. The strategic expansion and modernization of diagnostic infrastructure remain central to competitive positioning in this sector.

Scope & Segmentation of the Point-of-Care Lipid Testing Market

This report offers a robust segmentation structure to guide executive decision-making in investment and expansion strategy:

• Product Types: Consumables—including controls, kits, and reagents—are used alongside instruments such as benchtop and handheld analyzers to meet diverse operational and workflow requirements.
• End Users: Clinics, diagnostic laboratories, home testing settings, and hospitals each require tailored lipid management solutions for optimal efficiency and patient engagement.
• Technology: Laboratory systems utilize chromatographic, colorimetric, enzymatic, and immunoassay platforms to provide diagnostic flexibility and precision compatible with different healthcare infrastructures.
• Distribution Channels: Diagnostic laboratory distributors, e-commerce outlets, hospital pharmacies, and retail pharmacies facilitate widespread product adoption and reliable supply chains.
• Application Areas: Solutions span cardiovascular risk assessment, diabetes monitoring, and preventive screening, enabling organizations to support broad-based clinical initiatives and strengthen proactive health strategies.
• Regions: The Americas, Europe, Middle East & Africa, and Asia-Pacific offer varied growth opportunities based on local healthcare delivery models and regulatory environments.
• Leading Companies: Abbott Laboratories, Roche Diagnostics International AG, Siemens Healthineers AG, Nova Biomedical Corporation, PTS Diagnostics LLC, EKF Diagnostics Holdings plc, Trividia Health Inc., Chembio Diagnostics Inc., Arkray Inc., Meridian Bioscience Inc.

Executing on focused segmentation delivers value through efficient product design, streamlined supply chains, and targeted regional expansion, which are critical in the dynamic and regulated healthcare environment.

Key Takeaways for Senior Decision-Makers

• Decentralized diagnostic models expand lipid testing access, accelerating interventions for both urban and underserved populations to help reduce care disparities.
• Advanced analyzers increasingly integrate with electronic health records and telemedicine, facilitating real-time data sharing and more coordinated care delivery among clinical teams.
• Regulatory changes demand that product development cycles remain closely aligned with compliance requirements, supporting a nimbler response to evolving industry standards and guidelines.
• Collaboration between manufacturers, technology companies, and analytics providers continues to enhance the performance and sophistication of point-of-care testing solutions globally.
• Investment in analyzer hardware and digital platforms reduces the divide in quality and accessibility between varied clinical environments, contributing to better health outcomes and market reach.
• Strategic activities such as mergers, acquisitions, and increased R&D investment drive market resilience and broaden the role of lipid biomarkers in preventive diagnostics.

Tariff Impact: United States Supply Chain Shifts

Following 2025 tariff modifications affecting key testing components and reagents, U.S. companies with large import dependencies are adapting to increased operational costs. Many organizations are prioritizing domestic manufacturing and diversification of suppliers to safeguard supply chain continuity. While larger enterprises are equipped to implement structural supply chain adjustments for resilience, smaller firms weigh pricing strategies or possible consolidation to maintain a competitive market position.

Methodology & Data Sources

This report integrates direct insights from laboratory directors, clinicians, and regulatory authorities, alongside international regulatory documentation, patent reviews, and industry research. All data are cross-verified for accuracy and relevance to senior executive audiences.

Why This Report Matters

• Enables executive teams to align strategy with point-of-care lipid testing market trends, supporting adaptive and compliant planning as industry requirements evolve.
• Delivers actionable segmentation, technology, and regional insights to inform effective decisions in complex global healthcare markets.
• Assists organizations in proactively identifying supply chain, regulatory, and tariff risks, enabling robust, forward-looking business resilience.

Conclusion

This analysis offers healthcare and diagnostics leaders a comprehensive framework to leverage innovation, evaluate expansion opportunities, and manage risk throughout the market’s ongoing transformation.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.